...
首页> 外文期刊>Weed Technology: A journal of the Weed Science Society of America >Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19
【24h】

Heparan sulfate/heparin glycosaminoglycan binding alters inhibitory profile and enhances anticoagulant function of conserved Amblyomma americanum tick saliva serpin 19

机译:硫酸乙酰肝素/肝素糖胺聚糖结合改变了抑制型材并增强了保守的Amblyomma Americanum蜱酱油19的抗凝血功能

获取原文
获取原文并翻译 | 示例
           

摘要

Some serine protease inhibitor (serpin) regulators of essential life pathways bind glycosaminoglycans (GAGS) to enhance inhibitory functions and achieve physiologically relevant rates. This study demonstrates that highly conserved Amblyomma americanum tick saliva serpin 19 (AAS19), a broad-spectrum inhibitor of hemostasis and inflammation system proteases and anticoagulant, can bind heparan sulfate/heparin (HS)GAGs and that this interaction alters its function. Substrate hydrolysis and unpaired t-test analyses revealed that HSGAG binding caused rAAS19 inhibitory activity to: (i) significantly increase against blood clotting factors (f) Ila (thrombin) and flXa, (ii) significantly reduce against fXa and fXIIa and (iii) moderate to no effect against trypsin, kallikrein, papain, and plasmin. Stoichiometry of inhibition (SI) analyses show that HSGAG binding improved the rAAS19 inhibitory efficiency against thrombin 2.7-4.3 fold as revealed by SI change from 13.19 in absence of HSGAGs to 4.83-3.04 in their presence. Our data show that HSGAG binding dramatically enhanced rAAS19 anticoagulant function. In the recalcification time assay, rAAS19 pre-incubated with HSGAGs prior to the assay, delayed plasma clotting by an additional 176-457 s above HSGAGs or rAAS19 alone. Our data suggest that formation of the HSGAGs and rAAS19 complex is important for the observed enhanced anticoagulant effect. Delay of plasma clotting was higher when HSGAGs and rAAS19 were co-incubated to allow complex formation prior to blood clotting assay as opposed to no co-incubation. We have discussed our finding with reference to tick feeding physiology and utility of the rAAS19 in blood clotting disorder therapy. (C) 2016 Elsevier Ltd. All rights reserved.
机译:一些丝氨酸蛋白酶抑制剂(Serpin)的基本寿命途径调节剂结合糖胺聚糖(GAG)以增强抑制功能并达到生理相关的率。本研究表明,高度保守的Amblyomma Americanum蜱乳蛋白19(AAS19),止血抑制剂和炎症系​​统蛋白酶和抗凝血剂,可以结合硫酸乙酰肝素/肝素(HS)Gag,并且该相互作用改变其功能。底物水解和未配对的T检验分析显示Hsgag结合导致RAA19抑制活性:(i)显着增加血液凝血因子(F)ILA(凝血酶)和FLXA,(ii)显着减少对FXA和FXIIA和(III)的显着减少对胰蛋白酶,Kallikrein,木瓜蛋白和纤溶酶的反对没有影响。抑制的化学计量(Si)分析表明,HSGAG结合改善了凝血酶的RAA19抑制效率2.7-4.3折叠,从13.19的情况下揭示的SI变化在不存在下存在于4.83-3.04。我们的数据显示HSGAG绑定急剧增强了RAAS19抗凝功能。在重新计算时间测定中,RaAs19在测定之前预孵育Hsgags,仅通过Hsgags或Raas19的另外的176-457秒延迟等离子体凝固。我们的数据表明,Hsgags和Raas19复合物的形成对于观察到的增强的抗凝血效果很重要。当HSGAGS和RAA19共孵育时,血浆凝血的延迟较高,以允许在血液凝固测定之前允许复杂的形成,而不是NO CON孵育。我们已经参考滴血喂养生理学和效用在血液凝固障碍治疗中进行了探讨了。 (c)2016 Elsevier Ltd.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号